Cinctive Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Cinctive Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.38M	Sell	26,184 -43,975	-63%	-$1.81M	0.09%	230
2025 Q4	$2.83M	Sell	70,159 -7,396	-10%	-$171K	0.15%	171
2025 Q3	$582K	Sell	77,555 -32,442	-29%	-$207K	0.03%	340
2025 Q2	$410K	Hold	109,997	–	–	0.02%	325
2025 Q1	$304K	Hold	109,997	–	–	0.02%	284
2024 Q4	$609K	Sell	109,997 -58,567	-35%	-$397K	0.03%	310
2024 Q3	$1.41M	Buy	+168,564	New	+$1.39M	0.08%	260

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Cinctive Capital Management's TERN Position: Q1 2026 in Review

Cinctive Capital Management reduced its Terns Pharmaceuticals (TERN) stake by 63% in Q1 2026, selling an estimated $1.81M and leaving 26,184 shares worth $1.38M. The position accounts for 0.09% of the portfolio, ranked #230.

Cinctive Capital Management first reported a position in TERN in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.83M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Cinctive Capital Management held 26,184 shares of Terns Pharmaceuticals worth $1.38M as of Q1 2026.
Cinctive Capital Management sold 43,975 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.81M.
Terns Pharmaceuticals made up 0.09% of Cinctive Capital Management's portfolio in Q1 2026, its #230 holding.
Cinctive Capital Management first reported a position in Terns Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Cinctive Capital Management's Terns Pharmaceuticals position peaked at $2.83M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.